COMPANY

BCN PEPTIDES SA

BCN PEPTIDES SA: API manufacturer, bulk ingredient labeler for Angiotensin II, Calcitonin, Cetrorelix, Desmopressin, Ganirelix, Icatibant, Lanreotide, Leuprolide, Octreotide, Vasopressin, Terlipressin, as stated by public registers.

Also written as: BCN Peptides SA.

API MANUFACTURER

Filed a drug master file with FDA for the active ingredient.

Angiotensin IIDMF 36370, type II, active, submitted 2021-10-04 Regulator FDA drug master file list
CalcitoninDMF 19579, type II, active, submitted 2006-07-05 Regulator FDA drug master file list
CetrorelixDMF 38264, type II, active, submitted 2023-03-31 Regulator FDA drug master file list
DesmopressinDMF 19334, type II, active, submitted 2006-04-06 Regulator FDA drug master file list
GanirelixDMF 29585, type II, active, submitted 2015-07-24 Regulator FDA drug master file list
IcatibantDMF 29213, type II, active, submitted 2015-03-26 Regulator FDA drug master file list
LanreotideDMF 39254, type II, active, submitted 2023-12-21 Regulator FDA drug master file list
LeuprolideDMF 26716, type II, active, submitted 2012-12-11 Regulator FDA drug master file list
OctreotideDMF 18740, type II, active, submitted 2005-09-08 Regulator FDA drug master file list
VasopressinDMF 25736, type II, active, submitted 2012-01-24 Regulator FDA drug master file list

BULK INGREDIENT LABELER

Lists the bulk active ingredient with FDA (NDC directory).

CalcitoninSalmon Calcitonin, BULK INGREDIENT Regulator openFDA
DesmopressinDesmopressin acetate, BULK INGREDIENT Regulator openFDA
GanirelixGanirelix, BULK INGREDIENT Regulator openFDA
IcatibantIcatibant acetate, BULK INGREDIENT Regulator openFDA
LanreotideLanreotide acetate, BULK INGREDIENT Regulator openFDA
LeuprolideLeuprolide, BULK INGREDIENT Regulator openFDA
OctreotideOctreotide, BULK INGREDIENT Regulator openFDA
TerlipressinTerlipressin, BULK INGREDIENT Regulator openFDA
VasopressinVASOPRESSIN, BULK INGREDIENT Regulator openFDA

What a register states, not an endorsement or an accusation by this site. All companies.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.